Clinical Trial Update: Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the ITK inhibitor soquelitinib to reduce lymphoproliferation and improve cytopenias in Autoimmune Lymphoproliferative Syndro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Lymphoproliferative Syndrome

Drugs mentioned

• Soquelitinib

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Autoimmune Lymphoproliferative Syndrome | Phase 2 | Status: RECRUITING